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[Firstly, do no harm. How can we know this?] 
Drug-eluting stents versus surgery
A recently published record of patients with multiarterial 
coronary disease in the State of New York who underwent an-
gioplasty through emplacing drug-eluting stents, compared with 
patients treated with revascularization surgery, showed greater 
mortality in the group in which drug-eluting stents were used.1 
In addition to the greater mortality, the incidence of myocardial 
infarct or the need for additional revascularization was also 
greater in the group treated with percutaneous intervention 
using drug-eluting stents. 
At fi rst sight, this is prime-quality evidence, since the study 
included 9,963 patients treated with drug-eluting stents and 
7,437 with myocardial revascularization surgery. The follow-up 
lasted for around 18 months.1
These data reinforce the results from a systematic review 
with meta-analysis that was conducted by the Brazilian Cochrane 
Center for the Ministry of Health in 2004,2 as confi rmed sub-
sequently by other prospective studies and meta-analyses that 
demonstrated that bare-metal stents (cheaper) and drug-eluting 
stents were equivalent with regard to questions of mortality, 
incidence of infarct and need for surgical revascularization.3-10 
Obviously, belief in the physiopathological theory that the 
consequences of local fi broblastic proliferation are reduced 
through the use of drug-eluting stents has waned in the light of 
the mounting evidence.
Another systematic review conducted by the team at the 
Brazilian Cochrane Center also showed that there was a lack of 
evidence that drug-eluting stents had better results in relation to 
the most important outcomes than did bare-metal stents stents, 
in diabetic patients.3 
Some points should be made regarding the above informa-
tion: 
1) The effectiveness and safety	of new technology need to be 
subjected to comparisons, before millions of lives and billions 
of dollars are involved. Inadequate conduct involving failure 
to do this has been repeated ad infi nitum in Medicine.
2) Good medical science requires methodological rigor and 
absence of outside interests, emotions and fantasies, in order 
to reduce the uncertainties in decision-making and increase 
the effectiveness and effi ciency. There need to be method-
ological and critical improvements among the professionals 
involved in such activities. 
3) It is good strategy for the country and for our profession that 
the culture of practicing healthcare based on good evidence 
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should permeate all	sectors of healthcare decision-making 
and practice. The phrase “small mistakes with expensive new 
technologies” is almost a pleonasm, since almost all novelties 
reach requirements of around one billion reais per annum, 
from the Brazilian Ministry of Health, companies, patients 
and therefore taxpayers. 
4) It is good to bear in mind that the Brazilian Ministry of 
Health invests around 30 billion reais per annum. Consider-
ing that hundreds of products containing new technology 
are launched on the market every year, generally based on 
extremely limited evidence that is of much poorer quality 
than what the use of drug-eluting stents was based on, there 
are insuffi cient fi nancial resources to support this. And, the 
political and judicial pressures on the Ministry of Health 
and other administrative systems end up being very high. 
5) This phenomenon does not occur only with manufactured 
products. A large proportion of physiotherapeutic and 
so-called alternative procedures are also not based on good 
scientifi c evidence. Clinical trials and systematic reviews 
are still required, for such procedures to be used more or 
be discarded on the basis of scientifi c proof.
6) Teaching of Evidence-based Medicine needs to be obliga-
tory in all medical schools and in all health-related fi elds, 
because of the simple fact that it is necessary to separate 
effi ciency and safety from waste and/or harmful action. 
This is increasingly a fundamental role among physicians.
In short, there are many other lessons to be learned from 
the enormous number of examples of mistakes that have histori-
cally been repeated in Medicine since its earliest days and which 
have ended up compromising the marvelous results from highly 
benefi cial medical approaches. Moreover, some such methods 
have often been underutilized because of a lack of commercial 
interest in them. 
However, this editorial cannot be concluded without point-
ing out that the comparative study on the treatment of heart 
diseased patients in the State of New York referred to at the start 
of this text was a retrospective observational study that only 
took into account the cases of patients who continued to live 
in the region. Many cases were lost from the follow-up, thereby 
weakening the evidence, since patients who disappear may have 
died, and this could change the results. Thus, the small differ-
ences in mortality and infarction rates might disappear.
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Although the study sample was large and 
great effort was required to conduct the study, 
the level of evidence is lower than in a good 
clinical trial or a systematic review of clinical 
trials. Furthermore, the study in question 
did not incorporate comparisons with any 
equivalent group that only received clinical 
treatment. Therefore, it remains possible that 
surgery is better than or the same as drug-elut-
ing stents, but we do not known by how much 
it would be superior to clinical treatment.
In other words, we have to adjust to prac-
ticing medicine based on the best evidence 
existing and continue to improve research 
methodology and our ability to critically 
assess new technologies. Through this, we 
will make fewer mistakes and can prepare 
new generations of teachers, researchers and 
healthcare professionals to face new techno-
logical challenges. The large numbers and 
seductive powers of such challenges tend 
to obscure decision-making by physicians, 
patients, managers, judges and ultimately 
all of society. In this respect, those who are 
responsible for capacitating new healthcare 
professionals have an extremely important 
role at the levels of undergraduate training 
and postgraduate research.
So what should be done? We remain 
with the conclusions from systematic reviews 
like the Cochrane reviews, which show that 
the use of drug-eluting stents reduces the 
incidence of restenosis in the treated vessel but 
does not reduce the rates of infarct or death, or 
the need for myocardial revascularization.
And the management of such cases? 
Whenever possible, decisions should be made 
by informed physicians and by patients who 
have been given explanations regarding the 
advantages and disadvantages of the options. 
If the patient is funding his own treatment, he 
may choose the most expensive option, if he 
believes that reducing the need for angioplasty 
has a worthwhile cost-benefit relationship. 
Those who are responsible for public 
healthcare policies or health insurance policies 
may take the view that restenosis does not 
increase the risks of infarct, death or the need 
for revascularization surgery, and therefore 
there is no clinical or economic advantage that 
would justify the expenditure. They thus may 
invest the difference in better treatment for 
arterial hypertension, hypercholesterolemia, 
sedentarism, obesity and secondary preven-
tion against infarct, using aspirin and other 
methods that are clearly efficient and safe. And 
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the new technologies, as ever, will continue to 
be improved in order to attain the necessary 
effectiveness, efficiency and safety.
Speaking of this, a clinical trial published 
by Vlaar et al. in Lancet on June 7, 2008, 
reported that percutaneous aspiration of the 
coagulum in the coronary artery within the 
first hours of the infarction, when compared 
with expansion using a balloon (stents were 
placed in both groups), reduced mortality 
and the rate of recurrence of infarct by almost 
50%, after one year of follow-up. There were 
536 individuals in the aspiration group and 
other 536 in the control group. In other 
words, it seems that this study was a major 
progress at extremely low cost. Long live 
evidence-based technology!11
Álvaro Nagib Atallah. Physician. Titular professor and head of 
the Discipline of Emergency Medicine and Evidence-Based 
Medicine of Universidade Federal de São Paulo — Escola 
Paulista de Medicina (Unifesp-EPM). Director of the Brazilian 
Cochrane Center and Scientific Director of Associação Pau-
lista de Medicina (APM). E-mail: atallahmbe@uol.com.br.
